TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Brief Summary: The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.

A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis.

A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.


Options:
A: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 70 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 70 mg SC | Arm Label: 280 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 280 mg SC | Arm Label: 210 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg SC | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 70 mg SC; Assigned to Arm(s): 70 mg SC | Intervention Type: DRUG; Name: 210 mg SC; Assigned to Arm(s): 210 mg SC | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC | Intervention Type: DRUG; Name: 280 mg SC; Assigned to Arm(s): 280 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Brief Summary: The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.

A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis.

A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Brief Summary: The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.

A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis.

A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.


Options:
A: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Arm Label: Ustekinumab cohort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bimekizumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab cohort, Placebo | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Ustekinumab cohort
B: Arm Label: Placebo-controlled Phase:; Type: EXPERIMENTAL; Interventions: Other: Placebo | Arm Label: Placebo-controlled Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Extension Phase: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Extension Phase: Apremilast 30 mg, Placebo-controlled Phase: Apremilast 30 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo-controlled Phase:
C: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Intraoperative Low Dose Adrenaline on Bleeding in Total Hip Arthroplasty - a Randomized Placebo-controlled Trial
Brief Summary: The purpose of this study is to evaluate the effect of intraoperative administration of low-dose adrenaline on intraoperative blood loss in patients undergoing hip surgery.


Options:
A: Arm Label: TXA + IIM; Type: EXPERIMENTAL; Interventions: Drug: Iron Isomaltoside 1000, Drug: Tranexamic Acid | Arm Label: Placebo TXA + IIM; Type: EXPERIMENTAL; Interventions: Drug: Iron Isomaltoside 1000, Drug: Placebos tranexamic acid | Arm Label: TXA + Placebo IIM; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Placebos iron isomaltoside 1000 | Arm Label: Placebo TXA + Placebo IIM; Type: EXPERIMENTAL; Interventions: Drug: Placebos iron isomaltoside 1000, Drug: Placebos tranexamic acid | Intervention Type: DRUG; Name: Iron Isomaltoside 1000; Assigned to Arm(s): Placebo TXA + IIM, TXA + IIM | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA + IIM, TXA + Placebo IIM | Intervention Type: DRUG; Name: Placebos iron isomaltoside 1000; Assigned to Arm(s): Placebo TXA + Placebo IIM, TXA + Placebo IIM | Intervention Type: DRUG; Name: Placebos tranexamic acid; Assigned to Arm(s): Placebo TXA + IIM, Placebo TXA + Placebo IIM
B: Arm Label: Intravenous tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5g intravenous Exacyl | Arm Label: Intra-articular tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: 3.0g intra-articular Exacyl | Intervention Type: DRUG; Name: 1.5g intravenous Exacyl; Assigned to Arm(s): Intravenous tranexamic acid | Intervention Type: DRUG; Name: 3.0g intra-articular Exacyl; Assigned to Arm(s): Intra-articular tranexamic acid
C: Arm Label: Adrenaline; Type: EXPERIMENTAL; Interventions: Drug: Adrenaline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)
Brief Summary: The purpose of the study is to determine whether buprenorphine is a beneficial, safe, cost effective treatment alternative to morphine sulfate in the treatment of Neonatal Abstinence Syndrome (NAS).


Options:
A: Arm Label: Song of Kin; Type: EXPERIMENTAL; Interventions: Behavioral: Song of Kin | Arm Label: Gato box; Type: EXPERIMENTAL; Interventions: Other: Gato box | Arm Label: Ocean disc; Type: EXPERIMENTAL; Interventions: Other: Ocean disc | Arm Label: Contingent singing; Type: EXPERIMENTAL; Interventions: Other: Contingent singing | Arm Label: Tonal Vocal holding; Type: EXPERIMENTAL; Interventions: Other: Tonal Vocal holding | Arm Label: Muted shaker; Type: EXPERIMENTAL; Interventions: Other: Muted shaker | Intervention Type: BEHAVIORAL; Name: Song of Kin; Assigned to Arm(s): Song of Kin | Intervention Type: OTHER; Name: Gato box; Assigned to Arm(s): Gato box | Intervention Type: OTHER; Name: Ocean disc; Assigned to Arm(s): Ocean disc | Intervention Type: OTHER; Name: Contingent singing; Assigned to Arm(s): Contingent singing | Intervention Type: OTHER; Name: Tonal Vocal holding; Assigned to Arm(s): Tonal Vocal holding | Intervention Type: OTHER; Name: Muted shaker; Assigned to Arm(s): Muted shaker
B: Arm Label: Standard therapy plus Aromatherapy; Type: EXPERIMENTAL; Interventions: Drug: lavender and chamomile essential oils | Arm Label: Standard therapy ALONE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lavender and chamomile essential oils; Assigned to Arm(s): Standard therapy plus Aromatherapy
C: Arm Label: Oral morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Oral morphine sulfate
D: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Adults
Brief Summary: The purpose of this trial is to determine whether the new inactivated polio vaccine that is based on attenuated poliovirus strains is safe and to evaluate the immune response in healthy adults.


Options:
A: Arm Label: IPV Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix | Intervention Type: BIOLOGICAL; Name: Poliorix; Assigned to Arm(s): IPV Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group B
C: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group
D: Arm Label: Sabin-IPV; Type: EXPERIMENTAL; Interventions: Drug: Sabin-IPV | Arm Label: Adjuvanted Sabin-IPV; Type: EXPERIMENTAL; Interventions: Drug: Adjuvanted Sabin-IPV | Arm Label: IPV; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPV | Intervention Type: DRUG; Name: IPV; Assigned to Arm(s): IPV | Intervention Type: DRUG; Name: Sabin-IPV; Assigned to Arm(s): Sabin-IPV | Intervention Type: DRUG; Name: Adjuvanted Sabin-IPV; Assigned to Arm(s): Adjuvanted Sabin-IPV

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
Brief Summary: The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.


Options:
A: Arm Label: Teriparatide; Type: EXPERIMENTAL; Interventions: Drug: Teriparatide, Drug: Placebo, Drug: Calcium, Drug: Vitamin D | Arm Label: Risedronate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate, Drug: Placebo, Drug: Calcium, Drug: Vitamin D | Intervention Type: DRUG; Name: Teriparatide; Assigned to Arm(s): Teriparatide | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Risedronate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Risedronate, Teriparatide | Intervention Type: DRUG; Name: Calcium; Assigned to Arm(s): Risedronate, Teriparatide | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Risedronate, Teriparatide
B: Arm Label: Alendronate 70 mg; Type: EXPERIMENTAL; Interventions: Drug: Alendronate, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Risendronate placebo | Arm Label: Risendronate 35 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate 35 mg, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Alendronate placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Risedronate 35 mg; Assigned to Arm(s): Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Elemental Calcium; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DRUG; Name: Risendronate placebo; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Alendronate placebo; Assigned to Arm(s): Risendronate 35 mg
C: Intervention Type: DRUG; Name: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: risedronate / Duration of Intervention: 12 mo; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium Carbonate, Drug: Vitamin D3 | Arm Label: Risedronate; Type: EXPERIMENTAL; Interventions: Drug: Calcium Carbonate, Drug: Vitamin D3, Drug: Risedronate | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Drug: Calcium Carbonate, Drug: Vitamin D3, Behavioral: Bone-loading exercises | Intervention Type: DRUG; Name: Calcium Carbonate; Assigned to Arm(s): Control, Exercise, Risedronate | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Control, Exercise, Risedronate | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Risedronate | Intervention Type: BEHAVIORAL; Name: Bone-loading exercises; Assigned to Arm(s): Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study alirocumab (REGN727/SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT).


Options:
A: Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT), Drug: Antihyperglycemic Drug | Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Lipid-Modifying Therapy (LMT), Drug: Antihyperglycemic Drug | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W | Intervention Type: DRUG; Name: Antihyperglycemic Drug; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W
B: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Alirocumab 75 mg/up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin), Drug: alirocumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LMT (atorvastatin, simvastatin, or rosuvastatin); Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: alirocumab; Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Progression of Atrial Fibrillation After a Failed Initial Ablation Procedure in Patients With Paroxysmal Atrial Fibrillation: A Randomized Comparison of the Drug Therapy Versus Re-Ablation
Brief Summary: The hypothesis of this study was that early re-ablation (test) was superior to AAD therapy (control) in patients with previous failed PVI ablation for paroxysmal AF.


Options:
A: Arm Label: AAD therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone), Procedure: ILR implantation | Arm Label: re-ablation procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: re-ablation procedure, Procedure: ILR implantation | Intervention Type: DRUG; Name: Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone); Assigned to Arm(s): AAD therapy | Intervention Type: PROCEDURE; Name: re-ablation procedure; Assigned to Arm(s): re-ablation procedure | Intervention Type: PROCEDURE; Name: ILR implantation; Assigned to Arm(s): AAD therapy, re-ablation procedure
B: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug
C: Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy
D: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy

Answer: A